Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 966.05 INR
Change Today +10.50 / 1.10%
Volume 45.7K
As of 7:06 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

piramal enterprises ltd (PIEL) Snapshot

Open
954.80
Previous Close
955.55
Day High
970.00
Day Low
954.40
52 Week High
05/20/15 - 1,045
52 Week Low
07/25/14 - 616.00
Market Cap
166.7B
Average Volume 10 Days
57.9K
EPS TTM
165.17
Shares Outstanding
172.6M
EX-Date
07/28/15
P/E TM
5.8x
Dividend
20.00
Dividend Yield
5.43%
Current Stock Chart for PIRAMAL ENTERPRISES LTD (PIEL)

Related News

No related news articles were found.

piramal enterprises ltd (PIEL) Related Businessweek News

No Related Businessweek News Found

piramal enterprises ltd (PIEL) Details

Piramal Enterprises Limited primarily manufactures and sells own and traded bulk drugs and formulations in India and internationally. It operates through three segments: Pharmaceuticals Businesses, Financial Services Businesses, and Information Management Business. The company provides custom manufacturing services across the entire drug lifecycle ranging from development and commercial manufacturing to off-patent supplies of active pharmaceutical ingredients and formulations. It also manufactures and sells inhalation anaesthetics, such as Halothane, Isoflurane, and Sevoflurane; Propofol; and plasma volume expanders, including Polygeline. In addition, the company offers vitamins and nutrition, analgesics, dermatological, antacids, and cough and cold products under various brands, such as Saridon, Lacto Calamine, i-Pill, Itchmosol, Supractiv Complete, Polycrol, i-Sure, i-Can, Jungle Magic, Tetmosol, and Triactiv; and lipids and immunoturbidimetric HbA1c kits to bio-chemistry analysers, hematology analysers, and diasys range of reagents. Further, it develops various medicines that are in Phase I trials comprising GPR40 agonist - P11187, an oral anti-diabetic molecule; P7435, a DGAT1 inhibitor that addresses multiple aspects of metabolic syndrome; and P1446 and P7170 for oncology. Additionally, the company offers Neuraceq, an imaging agent; BST-CarGel, a bio-scaffold for cartilage regeneration; and focuses on the research and commercialization of natural products and herbal medicines. It also offers finance to real estate developers; structured finance transaction services for infrastructure companies; and data analytics services to pharmaceutical, medical device, managed care, and other healthcare industry customers, as well as is engaged in NBFC operations. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

Founded in 1947

piramal enterprises ltd (PIEL) Top Compensated Officers

Chairman, Member of Nomination & Remuneration...
Total Annual Compensation: 63.0M
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 35.3M
Vice Chairperson
Total Annual Compensation: 30.1M
General Manager of Strategic Marketing, Execu...
Total Annual Compensation: 21.3M
Compensation as of Fiscal Year 2014.

piramal enterprises ltd (PIEL) Key Developments

Ramky Infrastructure To Sell Road Assets

Ramky Infrastructure Limited (BSE:533262) is in active discussions to sell four of its road assets, including Ramky Eslamex, Sehore Kosmi Tollways, Hyderabad Outer Ring Road and NAM Expressway, a senior company official told Financial Express (India). Ramky expect to receive INR 10 billion from the sale. Ramky may also sell a 1,200-acre land parcel on the outskirts of Hyderabad. "We are in active discussions with several buyers to sell these assets, and are hopeful of closing some transactions within this financial year itself," the official said. Piramal Enterprises Limited (BSE:500302) was interested in some assets, but talks had stopped, according to the official. "We are having parallel discussions with other interested buyers as well," the official added.

Piramal Enterprises Limited Recommends Dividend for the Financial Year Ended March 31, 2015

Piramal Enterprises Limited announced that the Board of Directors of the company at its meeting held on May 7, 2015, recommended dividend of INR 20 per equity share of face value of INR 2 (that is at 1,000%) for the financial year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the company.

Piramal Enterprises Limited Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

Piramal Enterprises Limited reported audited consolidated and standalone earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 12,893.4 million against INR 11,103.8 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 1,229.4 million against INR 61.7 million a year ago. Profit from ordinary activities before tax was INR 817.7 million against loss from ordinary activities before tax of INR 2,832.9 million a year ago. Net profit was INR 479.4 million or INR 5.5 per basic and diluted share before and after extra ordinary items against net loss of INR 3,113.5 million or INR 18.00 per basic and diluted share before and after extra ordinary items a year ago. OPBITDA was INR 1,940 million against INR 710 million a year ago. Profit before tax & exceptional items were INR 770 million against loss of INR 2,780 million a year ago. Operating profit for the quarter, primarily driven by strong revenue performance across most of the businesses during the quarter and fall in R&D expenses. The increase in net profit was mainly on account of improved performance across business segments, lower interest cost due to reduction in long term debt and higher share of income from associates, partly offset by marginal increase in depreciation. For the year, on consolidated basis, the company reported net sales/income from operations of INR 50,806.0 million against INR 44,644.3 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 5,956.1 million against INR 3,921.9 million a year ago. Profit from ordinary activities before tax was INR 30,353.5 million against loss of INR 4,347.7 million a year ago. Net profit was INR 28,499.5 million or INR 165.2 per basic and diluted share before and after extra ordinary items against loss of INR 5,014.1 million or INR 29.1 per basic and diluted share before and after extra ordinary items a year ago. OPBITDA was INR 8,850 million against INR 6,390 million a year ago. Profit before tax & exceptional items were INR 3,390 million against loss of INR 4,360 million a year ago. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 6,594.0 million against INR 4,777.8 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 1,054.4 million against INR 180.6 million a year ago. Profit from ordinary activities before tax was INR 885.6 million against loss of INR 2,013.9 million a year ago. Net profit was INR 726.9 million or INR 4.2 per basic and diluted share before and after extraordinary items against loss of INR 2,013.9 million or INR 11.6 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 22,797.3 million against INR 18,134.7 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 3,558.2 million against INR 1,351.6 million a year ago. Profit from ordinary activities before tax was INR 6,463.8 million against loss of INR 3,700.0 million a year ago. Net profit was INR 3,727.4 million or INR 21.6 per basic and diluted share before and after extraordinary items against loss of INR 3,700.0 million or INR 21.4 per basic and diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIEL:IN 966.05 INR +10.50

PIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 473.30 INR +11.85
Cambrex Corp $44.24 USD -0.61
Divi's Laboratories Ltd 1,859 INR +6.30
Jubilant Life Sciences Ltd 171.10 INR +2.25
Torrent Pharmaceuticals Ltd 1,322 INR +5.25
View Industry Companies
 

Industry Analysis

PIEL

Industry Average

Valuation PIEL Industry Range
Price/Earnings 5.8x
Price/Sales 3.2x
Price/Book 1.4x
Price/Cash Flow 5.2x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIRAMAL ENTERPRISES LTD, please visit pharmasolutions.piramal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.